We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PTAB to Review Alexion’s Soliris Patents as Amgen Cries Foul
PTAB to Review Alexion’s Soliris Patents as Amgen Cries Foul
The Patent Trial and Appeal Board (PTAB) said it’s opening an inter partes review (IPR) of patents covering Alexion Pharmaceuticals’ immunosuppressive drug Soliris (eculizumab), following a petition by Amgen.